Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are OCUL, HROW, TGTX, KROS, RYTM, and represent 42.22% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: JSPR (+$13M), LYEL (+$7.5M), CMPX (+$6.3M), OCUL (+$5.3M), APLT, NTLA, SVRA, NRIX, RVNC, ZNTL.
- Started 14 new stock positions in RGLS, RVNC, CMPX, JSPR, NRIX, RPTX, DSGN, LYEL, IBIO, GKOS. SVRA, ALLK, ZNTL, PMVP.
- Reduced shares in these 10 stocks: SLRN (-$17M), IDYA (-$11M), BHVN (-$8.6M), ARQT (-$6.3M), MRNS (-$6.1M), CRNX, RYTM, CPRX, LRMR, Jasper Therapeutics.
- Sold out of its positions in ARQT, IDYA, Jasper Therapeutics, KALV, MRNS, STRO, BHVN, KNSA.
- Opaleye Management was a net seller of stock by $-1.3M.
- Opaleye Management has $459M in assets under management (AUM), dropping by 22.90%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Opaleye Management
Opaleye Management holds 52 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Ocular Therapeutix (OCUL) | 13.2 | $61M | +9% | 6.7M | 9.10 |
|
Harrow Health (HROW) | 11.3 | $52M | +2% | 3.9M | 13.23 |
|
Tg Therapeutics (TGTX) | 7.6 | $35M | +2% | 2.3M | 15.21 |
|
Keros Therapeutics (KROS) | 5.3 | $24M | +2% | 368k | 66.20 |
|
Rhythm Pharmaceuticals (RYTM) | 4.9 | $22M | -15% | 515k | 43.33 |
|
Catalyst Pharmaceutical Partners (CPRX) | 3.5 | $16M | -20% | 1.0M | 15.94 |
|
Arvinas Ord (ARVN) | 3.0 | $14M | +25% | 330k | 41.28 |
|
Iovance Biotherapeutics (IOVA) | 2.9 | $13M | 897k | 14.82 |
|
|
Jasper Therapeutics Com New (JSPR) | 2.8 | $13M | NEW | 436k | 29.36 |
|
Edgewise Therapeutics (EWTX) | 2.6 | $12M | -4% | 665k | 18.24 |
|
Applied Therapeutics (APLT) | 2.6 | $12M | +62% | 1.8M | 6.80 |
|
4d Molecular Therapeutics In (FDMT) | 2.4 | $11M | +11% | 344k | 31.86 |
|
Codexis (CDXS) | 2.4 | $11M | +2% | 3.1M | 3.49 |
|
Protara Therapeutics Com Stk (TARA) | 2.4 | $11M | 2.7M | 4.01 |
|
|
Acelyrin (SLRN) | 2.3 | $11M | -61% | 1.6M | 6.75 |
|
Crinetics Pharmaceuticals In (CRNX) | 2.1 | $9.8M | -31% | 210k | 46.81 |
|
Eton Pharmaceuticals (ETON) | 2.0 | $9.2M | -3% | 2.4M | 3.75 |
|
Trevi Therapeutics (TRVI) | 2.0 | $9.1M | +4% | 2.6M | 3.45 |
|
Lyell Immunopharma (LYEL) | 1.6 | $7.5M | NEW | 3.4M | 2.23 |
|
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $7.5M | +18% | 315k | 23.65 |
|
Ventyx Biosciences (VTYX) | 1.5 | $7.1M | +12% | 1.3M | 5.50 |
|
Intellia Therapeutics (NTLA) | 1.5 | $7.0M | +157% | 255k | 27.51 |
|
Compass Therapeutics (CMPX) | 1.4 | $6.3M | NEW | 3.2M | 1.98 |
|
Xoma Corp Del Com New (XOMA) | 1.3 | $6.0M | 250k | 24.05 |
|
|
Liquidia Corporation Com New (LQDA) | 1.3 | $5.8M | -11% | 395k | 14.75 |
|
Vaxcyte (PCVX) | 1.3 | $5.8M | -5% | 85k | 68.31 |
|
Nyxoah S A SHS (NYXH) | 0.9 | $4.3M | -7% | 320k | 13.49 |
|
Savara (SVRA) | 0.9 | $4.3M | NEW | 855k | 4.98 |
|
Syros Pharmaceuticals Com New (SYRS) | 0.9 | $4.2M | +119% | 788k | 5.35 |
|
Urogen Pharma (URGN) | 0.9 | $4.1M | -15% | 270k | 15.00 |
|
Nurix Therapeutics 67080M103 (NRIX) | 0.9 | $3.9M | NEW | 267k | 14.70 |
|
Revance Therapeutics (RVNC) | 0.8 | $3.9M | NEW | 785k | 4.92 |
|
Relmada Therapeutics (RLMD) | 0.8 | $3.5M | -13% | 759k | 4.65 |
|
Protagonist Therapeutics (PTGX) | 0.7 | $3.3M | 113k | 28.93 |
|
|
Gossamer Bio Note 5.000% 6/0 (Principal) | 0.7 | $3.2M | 8.0M | 0.40 |
|
|
Zentalis Pharmaceuticals (ZNTL) | 0.7 | $3.2M | NEW | 200k | 15.76 |
|
Allakos (ALLK) | 0.7 | $3.1M | NEW | 2.4M | 1.26 |
|
Gossamer Bio (GOSS) | 0.6 | $2.9M | -18% | 2.4M | 1.18 |
|
Ibio Com New (IBIO) | 0.6 | $2.8M | NEW | 680k | 4.06 |
|
Verastem Com New (VSTM) | 0.5 | $2.5M | 211k | 11.80 |
|
|
Aligos Therapeutics (ALGS) | 0.3 | $1.6M | +25% | 1.6M | 0.98 |
|
Context Therapeutics (CNTX) | 0.3 | $1.5M | +13% | 1.1M | 1.38 |
|
Precigen (PGEN) | 0.3 | $1.4M | -6% | 948k | 1.45 |
|
Larimar Therapeutics (LRMR) | 0.3 | $1.3M | -72% | 174k | 7.59 |
|
Fulcrum Therapeutics (FULC) | 0.3 | $1.2M | 130k | 9.44 |
|
|
Morphosys Sponsored Ads (MOR) | 0.3 | $1.2M | -55% | 65k | 18.14 |
|
Glaukos (GKOS) | 0.2 | $809k | NEW | 8.6k | 94.29 |
|
Pmv Pharmaceuticals (PMVP) | 0.2 | $802k | NEW | 472k | 1.70 |
|
Biodesix (BDSX) | 0.2 | $765k | +7% | 535k | 1.43 |
|
Regulus Therapeutics (RGLS) | 0.1 | $491k | NEW | 170k | 2.88 |
|
Design Therapeutics (DSGN) | 0.1 | $456k | NEW | 113k | 4.03 |
|
Repare Therapeutics Ord (RPTX) | 0.1 | $318k | NEW | 68k | 4.71 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2024 Q1 restated filed May 29, 2024
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022
- Opaleye Management 2022 Q1 filed May 16, 2022
- Opaleye Management 2021 Q4 filed Feb. 14, 2022
- Opaleye Management 2021 Q3 filed Nov. 16, 2021
- Opaleye Management 2021 Q2 filed Aug. 16, 2021
- Opaleye Management 2021 Q1 filed May 18, 2021
- Opaleye Management 2020 Q4 filed Feb. 12, 2021
- Opaleye Management 2020 Q3 filed Nov. 16, 2020